Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of erythropoietin on renal function after kidney transplantation
2006-002938-38Phase 2Completed
- Sponsor
- Hannover Medical School
- Start
- Sep 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of epoetin alfa in end-stage kidney disease (ESKD) and Renal ischemia-reperfusion injury (RIRI), sponsored by Hannover Medical School. Primary endpoints: Serum creatinine concentration at day 42 post-transplant, Serum cystatin C concentration at day 42 post-transplant and 2 more. Started Sep 2006; status: completed.
02
Drugs
epoetin alfa
03
Conditions
end-stage kidney disease (ESKD)Renal ischemia-reperfusion injury (RIRI)
Beyond the preview
Go deeper on 2006-002938-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002938-38.